These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21786436)

  • 21. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
    Dick RJ; Dear AE; Byron KA
    Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
    Ono T; Kaikita K; Hokimoto S; Iwashita S; Yamamoto K; Miyazaki Y; Horio E; Sato K; Tsujita K; Abe T; Deguchi M; Tayama S; Sumida H; Sugiyama S; Yamabe H; Nakamura S; Nakagawa K; Ogawa H
    Thromb Res; 2011 Dec; 128(6):e130-6. PubMed ID: 21862109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.
    Minarik M; Kopeckova M; Gassman M; Osmancik P; Benesova L
    Electrophoresis; 2012 Apr; 33(8):1306-10. PubMed ID: 22589111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.
    Tazaki J; Jinnai T; Tada T; Kato Y; Makiyama T; Ikeda T; Yamane K; Naruse Y; Takahashi K; Watanabe H; Kimura T; Horiuchi H
    J Atheroscler Thromb; 2012; 19(2):186-93. PubMed ID: 22166969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
    Scott SA; Sangkuhl K; Stein CM; Hulot JS; Mega JL; Roden DM; Klein TE; Sabatine MS; Johnson JA; Shuldiner AR;
    Clin Pharmacol Ther; 2013 Sep; 94(3):317-23. PubMed ID: 23698643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
    Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS
    Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.
    Chae H; Kim M; Koh YS; Hwang BH; Kang MK; Kim Y; Park HI; Chang K
    Biomed Res Int; 2013; 2013():154073. PubMed ID: 23607088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
    Ford NF
    J Clin Pharmacol; 2009 May; 49(5):506-12. PubMed ID: 19246723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?
    Kassimis G; Stavrou EF; Alexopoulos D; Athanassiadou A
    Curr Pharm Des; 2013; 19(13):2489-95. PubMed ID: 23360266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
    Oestreich JH; Best LG; Dobesh PP
    Am Heart J; 2014 Mar; 167(3):413-8. PubMed ID: 24576527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel.
    Nishio R; Shinke T; Otake H; Sawada T; Haraguchi Y; Shinohara M; Toh R; Ishida T; Nakagawa M; Nagoshi R; Kozuki A; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
    Circ J; 2012; 76(10):2348-55. PubMed ID: 22785462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
    Price MJ; Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
    Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
    Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.